Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 18 December 2018, 10:38 HKT/SGT
Share:
    

Source: Eisai
Eisai: Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3's RNA Splicing Platform

Tokyo and New York, Dec 18, 2018 - (JCN Newswire) - Bristol-Myers Squibb Company (NYSE: BMY), Eisai Co., Ltd. and its U.S.-based precision medicine research & development subsidiary H3 Biomedicine, Inc. has announced a multi-year research collaboration focused on evaluating whether novel therapeutics leveraging H3's RNA splicing platform can provide a more powerful response against cancer.

The new collaboration will explore modulating RNA splicing to develop potential first-in-class therapies that would direct the immune system to target cancer cells and help more patients experience the benefits of immunotherapy.

Under the terms of the multi-year agreement, H3 and Bristol-Myers Squibb will jointly conduct the research focused on developing immune therapies using H3's RNA splicing platform. Bristol-Myers Squibb will be responsible for development and commercialization of selected compounds, and H3 is eligible to receive an upfront payment, development, regulatory and sales milestones as well as certain royalties according to sales revenue after launch. Eisai retains an option to co-develop and co-commercialize certain compounds that emerge from the collaborative research effort.

"We are excited to enter into this collaboration with Bristol-Myers Squibb, as we share a mutual commitment to discover and develop innovations that will help improve outcomes for patients," said Lihua Yu, Ph.D., president and chief data sciences officer at H3. "We have already advanced the first application of our RNA splicing platform into the clinic and look forward to building on that track record with research on this potential new immuno-oncology application together with Bristol-Myers Squibb, a leader in immuno-oncology. We believe this collaboration will help us better understand whether our RNA splicing platform can help enhance the immune system's ability to more effectively fight cancer."

"Bristol-Myers Squibb is looking forward to collaborating with H3 to advance the science and research around RNA splicing," said Percy Carter, head of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb. "H3 has deep expertise in defining the role of changes in RNA homeostasis that contribute to cancer. This collaboration will allow both companies to gain a deeper understanding about alterations in RNA splicing and an opportunity to discover new medicines that can potentially improve outcomes for patients."

"Since its inception, H3 has discovered potential new therapeutic options that leverage breakthroughs from cancer genomics and biotechnologies. We're very proud of this new research collaboration with Bristol-Myers Squibb, as it represents another critical milestone for H3 and an opportunity for patients," said Terushige Iike, president, Oncology Business Group at Eisai and chief executive officer at H3.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com.

About H3 Biomedicine

H3 Biomedicine, Inc., a Cambridge, Massachusetts-based biopharmaceutical company specializing in the discovery and development of precision oncology treatments using its integrated data science, human biology and precision chemistry discovery engine with the goal of improving the lives of patients. The company was established on December 2010 as a subsidiary of Eisai's U.S. pharmaceutical operation, Eisai Inc. H3 Biomedicine focuses on sustained long-term delivery of its pipeline, collaborating with Eisai Co., Ltd., who provides essential research funding and access to the capabilities and resources of a global pharmaceutical company. For more information, please visit www.h3biomedicine.com.


Contact:
Bristol-Myers Squibb
Carrie Fernandez
609-302-4342
carrie.fernandez@bms.com

H3 Biomedicine, Inc.
Liz Melone
617-256-6622
elizabeth_melone@h3biomedicine.com

Eisai Co., Ltd.
Public Relations
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 1, 2024 12:56 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Oct 31, 2024 12:56 HKT/SGT
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
Oct 31, 2024 10:33 HKT/SGT
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Oct 17, 2024 19:01 HKT/SGT
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
Oct 17, 2024 14:59 HKT/SGT
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: